As disparate representation in pivotal research impacts the outcomes of common diseases like lupus, clinicians and researchers alike are working to foster trust and collaboration with more patien...
The tool’s development for scoring severity among complex nail psoriasis cases and monitoring response to treatment may allow for improved outcomes among patients.
In an interview with HCPLive, Jha said clinicians should think of interventional approaches for treatment-resistant depression “sooner rather than later.”
https://www.hcplive.com/view/manish-jha-md-treatment-options-for-treatment-resistant-depression
McIntyre discusses how GLP-1 and GIP receptor agonists like semaglutide could potentially improve both acute and long-term measures of psychiatric disease.
https://www.hcplive.com/view/designing-semaglutide-study-psychiatry-roger-mcintyre-md
Glecaprevir/pibrentasvir is an effective treatment for HCV with high rates of SVR, even in patients with cirrhosis undergoing a shorter treatment regimen.
Jason Busse, DC, PhD, highlights the modest benefits of opioids and therapeutic cannabis in managing chronic pain.
A Veterans Affairs study finds low alpha-1 antitrypsin phenotyping rates, indicating the need for improved healthcare provider education on AATD.
https://www.hcplive.com/view/a1at-phenotyping-lags-behind-contributes-to-underrecognition-of-aatd
In an interview, Phillip explained the difference between OCD and body dysmorphic disorder, even though they are grouped in the DSM-5.
https://www.hcplive.com/view/katharine-phillips-md-differences-between-ocd-body-dysmorphic-disorder
A higher dietary intake of several nutrients was strongly associated with slower progression toward the central macula in eyes with non-central GA.
https://www.hcplive.com/view/dietary-nutrient-intake-linked-slower-geographic-atrophy-progression
Updates, case reports, and quizzes for rheumatologists on managing osteoporosis. Interpreting DXA and FRAX, new drug options, reducing fracture risks, and more.
Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.
https://www.hcplive.com/view/resources-for-patients-and-providers-on-adalimumab-biosimilars
Providers in inflammatory diseases discuss the instrumental role nurses and support staff play in educating patients on adalimumab biosimilars.
Drs Lio, Botsoglou, and Alexrad discuss the most asked questions and common concerns patients have on adalimumab biosimilars.
https://www.hcplive.com/view/common-questions-from-patients-about-adalimumab-biosimilars
These data suggest that a multidisciplinary clinic approach results in several benefits including reduced risk of cardiovascular events among those with psoriasis.
This clinical quiz will test your knowledge of the 2023 American Association for the Study of Liver Diseases/Infectious Diseases Society of America Hepatitis C guideline.
https://www.hcplive.com/view/clinical-quiz-hcv-daa-treatment-after-solid-organ-transplantation
At ARVO 2024, Roger Goldberg, MD explores the greater reductions in hard exudates achieved with faricimab than aflibercept in eyes with DME.
https://www.hcplive.com/view/roger-goldberg-md-impact-dual-inhibition-hard-exudates-dme
This analysis was designed to look into the timing and specific elements which mediate the relationship between eczema and systemic antibiotic use.
In an interview with HCPLive, Barnett discussed the ethical concerns of using psychedelics for treating substance use disorders.
https://www.hcplive.com/view/brian-barnett-md-psychedelics-fitting-into-the-suds-treatment-paradigm
Results suggest chronic hepatitis B virus is globally underassessed and undertreated, especially among women and Asian minorities in the West.
https://www.hcplive.com/view/study-highlights-global-disparities-hbv-evaluation-treatment
In an interview with Adler at APA 2024, he also explained how adults with ADHD may present additional symptoms not noted on the DSM when they have comorbidities.
https://www.hcplive.com/view/lenard-a-adler-md-symptoms-of-adhd-need-to-go-back-to-childhood-
These guidelines are designed to help clinicians incorporate the latest recommendations into their clinical practice.
https://www.hcplive.com/view/navigating-acr-s-ra-treatment-guidelines-with-bryant-england-md-phd
At ARVO 2024, Deepayan Kar, MD, PhD, describes the potential of measuring contrast sensitivity function using a novel gaze tracking-based VR headset in AMD.
https://www.hcplive.com/view/deepayan-kar-phd-ms-virtual-reality-approach-contrast-sensitivity-amd
Compass Pathways reports positive results for psilocybin in PTSD treatment, showing safety and symptom improvement in an open-label phase 2 study.
These data highlight the safety, efficacy, and long-term disease control results of treatment with topical ruxolitinib for a subpopulation of adolescents with atopic dermatitis.
Compass Pathways reports positive results for psilocybin in PTSD treatment, showing safety and symptom improvement in an open-label phase 2 study.
Sofosbuvir/velpatasvir/voxilaprevir rescue therapy was safe and effective, and SVR did not significantly differ based on genotype, cirrhosis, or first-line therapy.
https://www.hcplive.com/view/hcv-genotype-first-line-therapy-not-impact-salvage-therapy-response
An IMID diagnosis or use of immunomodulatory medications were not shown to be a significant risk factor of severe COVID-19 outcomes.
https://www.hcplive.com/view/comorbidities-pose-higher-risk-of-severe-covid-19-outcomes-than-imids
Dolly Chang, MD, PhD, describes results from an exploratory analysis on the long-term impact of rapid fluid reduction on outcomes in DME.
https://www.hcplive.com/view/dolly-chang-md-phd-importance-early-drying-outcomes-dme
Robert O. Cotes, MD, discusses why the proven agent clozapine may still be underutilized in schizophrenia.
https://www.hcplive.com/view/3-barriers-improving-clozapine-use-treatment-resistant-schizophrenia
These data from investigators at Trinity College Dublin highlighted the immune response mechanisms visible in children with atopic dermatitis.